- Cardiac Myosin Light Chain Kinase (cMLCK)
- rhNRG-1 variants
Neucardin™ is a recombinantly expressed portion of an endogenous protein found in the heart known as human neuregulin 1β2α. Neucardin™ is currently in Phase III clinical trials in China and has completed Phase II clinical trial in China, Australia and the United States. And it has also been approved to perform Phase III clinical trials in the US by FDA at the end of 2013.
Chronic Heart Failure is generally defined as the inability of the heart to supply sufficient blood flow to meet the needs of the body. The reasons for the hearts inability to pump blood to the body are complex, but include structure abnormalities in the cell known as myofibril disarray. Neucardin™ reverses the myofibril disarray to increase heart function.
Clinical studies demonstrate that Neucardin™ increases heart function in people with heart failure for up to 3 months and in China Phase 2 studies has a significant survival benefit with subjects with severe heart failure.
Zensun scientists identified a cardiac muscle cell kinase that can increase heart function in rats with heart failure. This enzyme is known as cardiac specific myosin light chain kinase. This will be a gene therapy candidate and we are looking for a partner for clinical development.
Clinical studies demonstrate that Neucardin™ increases heart function in people with heart failure for up to 3 months with a potential to increase survival.